Blog
About

6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Pneumocystis carinii pneumonia in a patient on etanercept for psoriatic arthritis.

      Irish Journal of Medical Science

      Arthritis, Psoriatic, drug therapy, immunology, Biopsy, Needle, Follow-Up Studies, Humans, Immunoglobulin G, adverse effects, therapeutic use, Immunohistochemistry, Immunosuppression, Immunosuppressive Agents, Male, Pneumonia, Pneumocystis, etiology, pathology, Receptors, Tumor Necrosis Factor, Risk Assessment, Severity of Illness Index, Treatment Outcome, Trimethoprim-Sulfamethoxazole Combination, Adult

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Pneumocystis carinii pneumonia (PCP) is a rare form of pneumonia associated with immune-suppression. It is common in patients with AIDS and with a CD4 count of less than 200 cells/mm(3). We report a case of PCP secondary to immune-suppression in a 41-year-old man with psoriatic arthritis being treated with the immune-modulatory agent etanercept. Diagnosis of PCP was made histologically using tissue obtained via transbronchial biopsy. There was a good response to standard treatment with high-dose co-trimoxazole. This report highlights a recognised but previously unreported complication of etanercept.

          Related collections

          Author and article information

          Journal
          17906888
          10.1007/s11845-007-0087-x

          Comments

          Comment on this article